Author: Sai Krishna

ZEISS CLINIC 360 receives FDA 510k clearance, amplifying patient care through simplified clinical insights

The ZEISS CLINIC 360 all-in-one browser-based software solution aggregates clinical data at scale and powers advanced analytics for streamlined ophthalmic workflows, providing clinicians with more time for personalizing patient care.

JENA, Germany, Aug. 19, 2026 /PRNewswire/ — ZEISS Medical Technology, one of the world’s leading medical technology companies, today announced the 510k clearance from the U.S. Food and Drug Administration (FDA) for ZEISS CLINIC 360¹. An all-in-one cloud and browser-based software solution, ZEISS CLINIC 360 combines diagnostic and medical data into a comprehensive patient view. By making relevant information easy to access and review, the solution helps clinicians evaluate disease progression, support treatment decisions, and improve workflow efficiency. ZEISS CLINIC 360 is part of the ZEISS ophthalmic workflow portfolio and will be available in the U.S. in early Fall 2026.

“Our strategic focus on digitally connected workflows, combined with the increasing adoption of digital ophthalmic tools in the U.S., has firmly positioned ZEISS at the forefront of empowering ophthalmologists. As ophthalmology continues to adopt connected technologies, clinicians need solutions that fit seamlessly into how their practice operates,” says Federico Villegas, Head of ZEISS Medical Technology U.S. and President of Carl Zeiss Meditec USA, Inc. “ZEISS CLINIC 360 reflects our commitment to reducing complexity across the care journey and helping practitioners work more efficiently while maintaining focus on their patients, marking a significant advancement toward the delivery of more personalized patient care.”

“Practices are dealing with increasing volumes of information from imaging devices, medical records, and diagnostic testing. With ZEISS CLINIC 360, our game-changing, cloud-based solution presents a truly comprehensive view of a patient, supporting a wide range of practices with actionable clinical insights and flexible configurations,” says Anuj Kalra, Head of Chronic Disease Management at ZEISS Medical Technology. “ZEISS CLINIC 360 represents a new standard in patient care support, helping clinicians identify meaningful change more quickly and spend less time searching for what they need.”

With the introduction of ZEISS CLINIC 360, ZEISS now offers eye care providers the flexibility to choose the data management approach that best fits their needs. While ZEISS FORUM continues to provide robust on-premise data management for practices that prefer local infrastructure, ZEISS CLINIC 360 delivers a cloud-based alternative that provides flexibility and scalability in a subscription-based model with low upfront costs and predictable monthly or annual payments.

Create a comprehensive patient overview

Combining information from diagnostic devices, electronic medical records, and practice systems, ZEISS CLINIC 360 creates a comprehensive patient record that allows clinicians to view their DICOM-enabled diagnostic device data – including CIRRUS^®, CLARUS^® and HFA^® from ZEISS, as well as third-party devices – to gain a unified, multi-modality view, enabling faster, more informed decisions to deliver high-quality, personalized care. ZEISS CLINIC 360 includes EMR integration² that seamlessly consolidates critical patient data – including risk factors, family history, allergies, and more – into the clinical workflow, organizing medical and diagnostic data together to present a comprehensive view of the patient’s condition.

Gain actionable clinical insights 

Leveraging disease-based summaries, interactive analysis, and collaboration tools, ZEISS CLINIC 360 transforms data into actionable clinical insights to enhance patient care. Clinicians can quickly monitor glaucoma progression, for example, with intuitive color-coded alerts and trend analysis of OCT, IOP and Visual Field data. ZEISS CLINIC 360 streamlines the clinical workflow with automated, interactive tools and analyses, providing greater efficiency across the workflow. When consultation is needed, clinicians can securely share cases and reports and request input from colleagues through integrated access to the ZEISS Collaborative Care feature, helping to facilitate improved patient care and referrals.

Designed for different clinical practice models

Built on the ZEISS Health Data Platform, ZEISS CLINIC 360 is accessed through the cloud or a web-based browser, enabling clinicians to review information across locations without requiring local software installation. Subscription options allow practices to select the configuration that best aligns with their operational and clinical requirements.

Not all products, services or offers are approved or offered in every market and approved labeling and instructions may vary from one country to another. For country-specific product information, see the appropriate country website. Product specifications are subject to change in design and scope of delivery as a result of ongoing technical development. The statements of the healthcare professionals reflect only their personal opinions and experiences and do not necessarily reflect the opinion of any institution that they are affiliated with. The healthcare professionals alone are responsible for the content of their experience reported and any potential resulting infringements. Carl Zeiss Meditec AG and its affiliates to not have clinical evidence supporting the opinions and statements of the health care professionals nor accept any responsibility or liability of the healthcare professionals’ content. The healthcare professionals have a contractual or other financial relationship with Carl Zeiss Meditec AG and its affiliates and have received financial support.

Contact for investors:

Sebastian Frericks

Director Investor Relations

Carl Zeiss Meditec AG

Phone: +49 3641 220 116

Mail: investors.med@zeiss.com

Contact for the press:

Frank Smith

Head of Global Communications

Ophthalmology, Carl Zeiss Meditec Inc.

Phone: +49 3641 220 331

Mail: press.med@zeiss.com

Company Profile

Carl Zeiss Meditec AG (ISIN: DE0005313704), which is listed on the TecDAX and SDAX of the German stock exchange, is one of the world’s leading medical technology companies. The Company supplies innovative technologies and application-oriented solutions designed to help doctors improve the quality of life of their patients. The Company offers complete solutions, including implants and consumables, to diagnose and treat eye diseases. The Company creates innovative visualization solutions in the field of microsurgery. With 5,784 employees worldwide, the Group generated revenue of €2,228m in fiscal year 2024/25 (to 30 September).

The Group’s head office is located in Jena, Germany, and it has subsidiaries in Germany and abroad; more than 50 percent of its employees are based in the USA, Japan, Spain and France. The Center for Application and Research (CARIn) in Bangalore, India and the Carl Zeiss Innovations Center for Research and Development in Shanghai, China, strengthen the Company’s presence in these rapidly developing economies. Around 39 percent of Carl Zeiss Meditec AG’s shares are in free float. Approx. 59 percent are held by Carl Zeiss AG, one of the world’s leading groups in the optical and optoelectronic industries.

For further information visit: www.zeiss.com/med

View original content to download multimedia:https://www.prnewswire.co.uk/news-releases/zeiss-clinic-360-receives-fda-510k-clearance-amplifying-patient-care-through-simplified-clinical-insights-302854994.html

Next Level Aviation® Appoints Mike Fleener as Senior Vice President of Global Sales

DANIA BEACH, Fla., Aug. 19, 2026 /PRNewswire/ — Next Level Aviation^® (NLA), a leader in the global distribution of used serviceable materials (USM) for all Boeing and Airbus commercial aircraft and associated jet engine platforms, has appointed Michael Fleener as Senior Vice President – Global Sales.

As a United States Military Academy graduate, former Army officer and Apache attack helicopter pilot who also has 20+ years in the commercial aviation aftermarket, Mr. Fleener brings significant leadership, sales, operations and supply chain experience to Next Level Aviation^®. Throughout his career, Mr. Fleener has worked in various roles for many of the largest companies in the commercial aviation aftermarket, including an OEM.

In his new role, Mike will leverage his leadership experience to lead, manage, develop and expand Next Level Aviation’s global sales team to grow its USM business in the coming years. He will also work closely SVP-Global Business Development Clive Rankin to expand Next Level Aviation’s global customer base.

Next Level Aviation^® CEO Jack Gordon commented, “We are pleased to add Mike Fleener as SVP-Global Sales at Next Level Aviation^®.” Gordon continued, “After 20 years in the commercial aviation aftermarket, Mike understands the USM needs of, and how to frame NLA’s value proposition to, our target end-user customers of airlines, leasing companies, MROs and OEMs. His analytical approach, willingness to mentor our existing sales team, and experience delivering results in fast-paced operating environments is exactly what Next Level Aviation^® needs to help drive this next stage of company growth.”

Senior Vice President – Global Sales Mike Fleener stated, “I am excited to join Next Level Aviation^® at such an important stage in the company’s growth. NLA has built an outstanding reputation for customer service, industry expertise, and delivering high-quality USM solutions to its global customer base. I look forward to working with the entire NLA team to expand our global customer relationships, develop our talented sales organization, and create long-term value for our customers and business partners.”

About Next Level Aviation^®

Next Level Aviation^® is an ASA-100 accredited, and FAA Advisory Circular 00-56B compliant supplier stocking commercial aircraft/jet engine used serviceable material (USM) for all Boeing and Airbus aircraft platforms and associated jet engines. Next Level Aviation^® specifically focuses on stocking USM for the Boeing 737 and Airbus A320 families of aircraft and their associated jet engines, which currently make up about 65% of the global commercial fleet. Founded in March 2013 by Jack Gordon, Next Level Aviation^® has grown into a top global supplier of commercial aircraft/jet engine used serviceable material. www.nextlevelaviation.net

To find out more information or to request additional images, please contact morgane@aerospacemarketing.com.

View original content to download multimedia:https://www.prnewswire.co.uk/news-releases/next-level-aviation-appoints-mike-fleener-as-senior-vice-president-of-global-sales-302854422.html

Dubai Police Initiatives Drive $176.4 Million in Social Value and Gains in Safety, Wellbeing and the Economy, Study Reveals

DUBAI, UAE, Aug. 19, 2026 /PRNewswire/ — A study has estimated the Social Return on Investment (SROI) of 80 Dubai Police community initiatives at AED 647.9 million ($176.4 million), reflecting the wider social, economic and security value created for 3.8 million beneficiaries between 2017 and 2026.

Conducted by the Future Foresight Centre, the study examined initiatives across education, health, awareness and sport and measured their contribution to security, economic and social outcomes, including public safety, crime prevention, trust in police and quality of life.

The study found that economic and community contributions accounted for AED 542.7 million ($147.8 million) of the total SROI. Initiatives supporting quality of life generated AED 31.7 million ($8.6 million), while AED 62.8 million ($17.1 million) was attributed to initiatives contributing to public trust. A further AED 5 million ($1.36 million) was linked to community wellbeing, while AED 5.7 million ($1.55 million) came from initiatives promoting accessibility and opportunities for participation across society.

The research also examined statistical relationships between community initiatives and key security and social indicators. It found positive correlations of 0.44 with the Happiness Index, 0.45 with the Happiness, Security and Awareness Index, and 0.44 with enhanced perceptions of safety.

The analysis also identified inverse relationships with crime related indicators. Increased implementation of community initiatives coincided with lower levels of concerning crimes, recording a negative correlation of 0.41. The study also found a negative 0.796 correlation between customer happiness and crime rates.

Lieutenant General Abdulla Khalifa Al Marri, Commander-in-Chief of Dubai Police, said the results reflect the effectiveness of developing sustainable community initiatives around society’s needs, while strengthening community partnerships and supporting quality of life. He described community initiatives as an important pillar of sustainable security, contributing to trust in police, perceptions of safety and crime prevention.

Among the initiatives assessed, ‘Positive Spirit’ initiative reached two million people, while Esaad benefited more than 1.15 million. Ride with Dubai Police reached 40,000 people, while activities associated with the UAE SWAT Challenge benefited 51,000.

The study also found that 7,189 volunteers contributed 249,916 hours between 2017 and 2026, generating estimated financial savings of AED 21.7 million ($5.9 million).

The findings show how sustained community engagement can translate into measurable social and economic value while supporting preventive security, stronger public trust, improved quality of life and greater social stability.

View original content to download multimedia:https://www.prnewswire.co.uk/news-releases/dubai-police-initiatives-drive-176-4-million-in-social-value-and-gains-in-safety-wellbeing-and-the-economy-study-reveals-302855312.html

Sino Biopharmaceutical Limited Unveils New Global Brand, SBP Group, to Accelerate International Expansion

HONG KONG, Aug. 19, 2026 /PRNewswire/ — Sino Biopharmaceutical Limited (HKEX: 01177), a leading innovation-driven pharmaceutical company in China, announced the launch of its new global brand, SBP Group, during its interim results meeting. SBP stands for Science, Breakthroughs and Patients: Science is where the company starts; breakthroughs are what it pursues; patients are why it does what it does. This philosophy aligns with the Company’s mission, “Science for a Healthier World.”

The unified identity reflects the Company’s strategic evolution from a leading domestic biopharmaceutical company into a global innovator. This transformation is advancing on two fronts: product globalization, by building a global pipeline of innovative assets through in-house R&D and acquisition; and business globalization, through global partnerships and direct commercial expansion in key international markets. Supported by continued investment in global talent, organizational capabilities and infrastructure, the Company aims to bring innovative medicines to more patients worldwide.  

“2026 marks the first year of executing our globalization strategy, and we have made strong progress,” said Ms. Theresa Tse, Chairwoman of the Board. “SBP Group is committed to working with global partners to accelerate the global development and availability of innovative medicines from China and bring cutting-edge therapies from around the world to China. Leveraging our AI-driven, fully integrated R&D platform, we aim to advance breakthroughs at the frontiers of science, with the ultimate goal of benefiting more patients and improving human health.”

To date, the Company has completed four out-licensing transactions with MNCs, with aggregate upfront payments exceeding US$1 billion and a total potential deal value of more than US$7 billion, alongside over 30 M&A, licensing and strategic partnership transaction. 2026 key transactions include (i) the exclusive licensing to Sanofi of rovadicitinib, a first-in-class dual JAK/ROCK inhibitor, in a transaction valued at up to US$1.53 billion; and (ii) the exclusive licensing to AstraZeneca of TQC3721, an inhaled PDE3/4 inhibitor for COPD, in a transaction valued at up to US$1.9 billion.

About SBP Group

Sino Biopharmaceutical Limited (HKEX: 01177), referred to herein as “SBP Group”, is a leading innovation-driven pharmaceutical company in China. The Company has end-to-end capabilities across full value chain, including R&D, manufacturing and commercialization. Its product portfolio covers a wide range of biologics and small molecule drugs, with a strong leadership position across four core therapeutic areas: oncology, liver/cardiometabolic diseases, respiratory/autoimmune diseases, and surgery/analgesia.

View original content to download multimedia:https://www.prnewswire.co.uk/news-releases/sino-biopharmaceutical-limited-unveils-new-global-brand-sbp-group-to-accelerate-international-expansion-302855206.html

Bybit’s RLUSD Hold & Earn Surpasses $50M AUC, Launches Phase 2 with Boosted XRP-RLUSD Rewards in Partnership with Ripple

DUBAI, UAE, Aug. 19, 2026 /PRNewswire/ — Bybit, the world’s second-largest cryptocurrency exchange by trading volume, is excited to announce its exclusive RLUSD Hold & Earn program is entering Phase 2, extending its partnership with Ripple. Starting now, the upgraded Bybit Earn campaign introduces dual daily rewards in both XRP and RLUSD, with total annualized returns scaling based on holding duration.

Bybit’s RLUSD Hold & Earn program, initially launched in July this year, accumulated over $50 million in Assets Under Custody (AUC) within 11 days, attracting yield-seekers with its simple structure, flexibility, and minimum hassle. Eligible Bybit users may simply hold RLUSD with no staking or lock-up required, drawing popular demand from holders seeking stable, low-friction yield opportunities.

Highlights – Phase 2

The second phase of the program retains the same user experience with added benefits, introducing APR multipliers for holders both by volume and by length of time:

• Dual-Token Rewards: Participants can now earn both RLUSD at a competitive base APR and XRP with bonus APR daily
• XRP Base APR Multiplier: Users who maintain their holdings for 30 days or more receive up to 2x bonus on the XRP portion, more than doubling the potential total APR
• Smooth User Journey: No subscription, no lock-up. Holding RLUSD is all it takes to earn APR automatically

XRP rewards are brought to the Bybit community by Ripple’s milestone-based incentive program, enabling holders to get the most of the Ripple ecosystem assets with confidence.

RLUSD is a USD-backed stablecoin issued by Ripple. Natively issued on XRP Ledger, Ethereum, and other blockchains. RLUSD is fully backed by a segregated reserve of cash and cash equivalents and redeemable 1:1 for US dollars. As a regulated, reserve-backed digital asset, RLUSD offers the price stability of traditional cash in onchain form.

Terms and conditions apply. For more details on the APR multiplier, eligibility, and potential restrictions, users may visit: RLUSD Hold & Earn Phase 2: Earn Up to 21.5% APR in XRP + RLUSD

#Bybit  / #NewFinancialPlatform

About Bybit

Bybit is The New Financial Platform.

We believe every person should have access to every financial opportunity on earth. That’s why we’re building the first intelligent platform that connects anyone, anywhere to the world’s finance.

Trusted by more than 80 million users worldwide, Bybit brings together investing, trading, payments, and wealth-building in a single secure and intelligent ecosystem. Through the combination of AI-powered technology, deep global liquidity, robust security, and transparent operations, Bybit makes global finance more accessible, efficient, and empowering for everyone.

Built for everyone. Powered by intelligence. Open to the world.

Learn more at Bybit.com

For more details about Bybit, please visit Bybit Press

For media inquiries, please contact: media@bybit.com

For updates, please follow: Bybit’s Communities and Social Media

Discord | Facebook | Instagram | LinkedIn | Reddit | Telegram | TikTok | X | Youtube

View original content to download multimedia:https://www.prnewswire.co.uk/news-releases/bybits-rlusd-hold–earn-surpasses-50m-auc-launches-phase-2-with-boosted-xrp-rlusd-rewards-in-partnership-with-ripple-302855213.html

Manipal Hospital Millers Road Launches Momstory, Bringing Comprehensive Maternity and Women’s Healthcare Under One Roof

BENGALURU, India, Aug. 19, 2026 /PRNewswire/ — A new chapter in women’s healthcare begins with a more personalised maternity experience, designed around the needs of every woman and mother, from pre-conception and pregnancy to childbirth, postnatal recovery and beyond.

With a focus on combining clinical expertise with personalised, compassionate care, Manipal Hospital Millers Road has launched Momstory, to bring together maternity services and comprehensive women’s healthcare under one roof. The initiative aims to create a supportive environment where women and their families can feel informed, confident and cared for throughout the different chapters of motherhood and women’s health.

Momstory offers dedicated support across the maternity journey, including pregnancy care, childbirth, postnatal recovery and postpartum wellness, supported by advanced medical infrastructure and multidisciplinary clinical expertise.

A key component of the initiative is the Premoms programme, which extends care beyond the hospital through a combination of online and offline wellness sessions. The programme brings together a multidisciplinary team comprising dietitians, physiotherapists, lactation consultants and psychologists, providing women with guidance and support from the pre-conception stage through pregnancy and into postpartum wellness.

The launch was graced by chief guest, Dr. Vidya Desai, Senior Consultant, who joined the team in marking the beginning of this new chapter in maternity, neonatal and paediatric care at Manipal Hospital Millers Road. Her presence added significance to the launch of Momstory and its vision of creating a more personalised and comprehensive care experience for mothers and children.

Speaking about the initiative, Dr. Geeth Monnappa, Lead Consultant – Obstetrics & Gynaecology at Manipal Hospital Millers Road, said, “Momstory is designed around the understanding that a woman’s healthcare journey extends well beyond the delivery room. From preparing for pregnancy to navigating motherhood and the many transitions that follow, women need continuous clinical guidance as well as emotional and practical support. Through Momstory and the Premoms programme, we aim to create a more connected care experience that supports women and their families at every step.”

Beyond maternity care, Momstory also addresses healthcare needs across different stages of a woman’s life through speciality clinics for PCOS, adolescent care and menopause care. These services are designed to provide specialised support during important transitional phases and address the evolving physical and emotional healthcare needs of women.

“The initiative also places emphasis on the overall patient experience. Through thoughtfully designed value-added services, Momstory seeks to make the journey of motherhood more comfortable, meaningful and memorable, while maintaining high standards of clinical care and safety,” said Dr. Mahima Bakshi, Strategy Consultant at Momstory Manipal Hospitals. “It’s a privilege to bring the Momstory brand to Manipal Hospitals. It has been a privilege for me to introduce the brand in South India, and we plan to take it across all our other units as well,” added Dr. Mahima.

With its launch at Manipal Hospital Millers Road, Momstory strengthens the hospital’s commitment to providing comprehensive, multidisciplinary and compassionate women’s healthcare, ensuring that women have access to the expertise and support they need across every stage of their lives.

For more information, please visit: https://www.manipalhospitals.com/

View original content to download multimedia:https://www.prnewswire.com/in/news-releases/manipal-hospital-millers-road-launches-momstory-bringing-comprehensive-maternity-and-womens-healthcare-under-one-roof-302855219.html

Hexaware Introduces Zero Vulnerability as AI Raises the Pressure on Enterprise Remediation

New security offering helps enterprises turn a growing volume of findings into fixes that can be verified in production

LONDON, Aug. 19, 2026 /PRNewswire/ — Hexaware Technologies (NSE: HEXT), an AI-first digital and IT services company, today announced Zero Vulnerability, a cybersecurity offering built for a growing problem facing enterprises. AI is helping vulnerabilities surface faster, while security and engineering teams still have finite capacity to investigate and fix them.

The Verizon 2026 Data Breach Investigations Report found only 26% of critical Known-Exploited Vulnerabilities were fully remediated last year, down from 38%. Median time to fully resolve them rose from 32 to 43 days. 99% of AI-discovered vulnerabilities still remain unremediated. Zero Vulnerability helps organizations sort through such findings, identify which ones pose the greatest risk, get the right teams working on them sooner, and verify that the vulnerability has been removed in production rather than simply marked as closed.

Delivered through Zerovity™, Hexaware’s AI-led delivery layer, the Zero Vulnerability offering combines its cybersecurity expertise, engineering, AI, and remediation operations across all variants of IT systems, including custom applications, SaaS and PaaS environments, third-party software, and operating systems. The remediation operating platform supports the lifecycle from ingestion and validation through prioritization, routing, fixing, verification, and closure. It works with existing security and workflow tools rather than requiring enterprises to replace them.

“AI is making vulnerability discovery dramatically faster, but enterprise remediation capacity remains finite. Zero Vulnerability is about changing that equation, cutting through the noise, identifying what truly matters, accelerating remediation, and proving that critical exposure has actually been removed. Our objective is simple: make risk fall faster than new findings arrive,” said Mohit Vaish, EVP & Business Head – Cybersecurity, Hexaware.

Hexaware’s own evaluation shows why validation is important. Across four detection lanes on production codebases, 334 findings were consolidated, of which 14 were ultimately verified as real. The evaluation also included a developer-validated review of 262 findings and identified a new authentication-bypass weakness that pattern-based rules had missed.

“The work required to remediate a vulnerability depends on where it sits. Custom code, operating systems, third-party products, and SaaS platforms all call for different actions and different ownership. Zero Vulnerability gives teams a consistent way to prioritize and manage that work across the technology estate, while AI helps get each issue to the right action and owner faster,” said Siddharth Dhar, President & Global Head, Digital IT Operations & AI, Hexaware.

Zero Vulnerability is a key pillar of Hexaware’s Zero Friction Enterprise™ and supports its broader approach to continuous exposure reduction, identity-first security, cyber defense, and AI-native security operations.

For more information, visit https://hexaware.com/zero-friction-enterprise/zero-vulnerability/.

About Hexaware

Hexaware is a global technology and business process services company. Every day, Hexawarians wake up with a singular purpose: to create smiles through great people and technology. With offices across the world, we empower enterprises worldwide to realize digital transformation at scale and speed by partnering with them to build, transform, run, and optimize their technology and business processes. Learn more about Hexaware at https://hexaware.com.

View original content to download multimedia:https://www.prnewswire.co.uk/news-releases/hexaware-introduces-zero-vulnerability-as-ai-raises-the-pressure-on-enterprise-remediation-302855184.html

Cellebrite Genesis for Enterprise Now Generally Available, Regional Availability Expands to More Global Markets

TYSONS CORNER, Va. and PETAH TIKVA, Israel, Aug. 19, 2026 /PRNewswire/ — Cellebrite DI Ltd. (Nasdaq: CLBT), a global leader in AI-powered Digital Investigative and Intelligence solutions for the public and private sectors, today announced that Cellebrite Genesis is expanding to more global markets and is now generally available for enterprise organizations. The expansion builds on a successful early access program and strong momentum following Genesis’ June 2026 public safety launch. Genesis has seen meaningful user growth worldwide and continues to expand internationally, with availability now in Australia and the United Kingdom and is expected to be available to the European Union later this month. 

Made generally available for the public sector in June, Genesis is serving a growing mix of national, regional and local agencies around the world, including some of the world’s largest regional and metropolitan police departments along with public safety departments, law enforcement agencies, prosecutors’ offices and correctional facilities of varying sizes.

Purpose-built for a broad range of corporate investigations, Genesis helps enterprise teams move from manual evidence review to AI-assisted investigation that surfaces connections in minutes rather than weeks for internal corporate investigations spanning employee misconduct to financial fraud, M&A due diligence, insider threat and incident response, eDiscovery pre-processing and regulatory and compliance matters.

As Cellebrite customers apply Genesis to active cases, the impact is tangible, accelerating the speed and efficacy of investigations across an array of crime types such as crimes against children, narcotics, human trafficking, homicide and cold cases. The following examples demonstrate how Genesis helps investigators move faster, uncover missed connections and turn digital evidence into action:

• Averting a planned school shooting: Following the arrest of a young student who threatened to commit a school shooting, investigators queried his phone data in Genesis and, within five prompts, identified and apprehended a second student across the country plotting a similar attack.
• Surfacing evidence that helped protect children: Genesis surfaced new information that had been missed in the initial manual review of a suspect’s device, giving investigators the probable cause needed to arrest an accused child predator after a year-long investigation.
• Converting prison conversations into actionable intelligence: A major law enforcement agency used Genesis to analyze three months of phone calls by five prison inmates and identified three minutes of conversations that involved the location of illegal firearms. As a result, the police seized more than 200 guns and arrested three suspects as part of a broader investigation.
• Validating findings in a high-profile corporate investigation: In a case of potential financial wrongdoing tied to a scrapped IPO, it took investigators months to piece together who was involved — running the same data through Genesis surfaced it in minutes, while validating the findings. 
• Triaging large video and audio files so a private digital forensics company could quickly isolate 20 video clips showing evidence of a crime, helping their client move the case forward quickly rather than needing to rely on manual review that would have taken days.
• Uncovering a terrorist financing network: After two months of manual review, a regional police agency used Genesis to immediately gain information about a suspected terrorist finance network.
• Validating new leads in a missing person cold case: A small county sheriff’s department received a new tip related to a cold case. Investigators used Genesis to query all the records, and they were able to immediately determine the new information was not relevant to the case; manually running down this lead would have taken weeks.

“Genesis was built on the belief that evidence should move at the speed the investigation demands. In two months, that belief has scaled from early access to a proven solution that is trusted on multiple continents, and now, with enterprise availability, we’re bringing that approach to the organizations who want to protect themselves from fraud, insider threats and data theft,” said Shiven Ramji, CEO of Cellebrite. “It is exciting to hear the impact Genesis is having on investigations and our customer feedback. Genesis is an example of the rapid innovation our customers can expect, ensuring we can deliver on our mission of protecting communities, nations and businesses.”

Innovation within Genesis continues to move forward. The Company also added Deep Investigator, a new capability for mobile extractions. Deep Investigator surfaces data that usually resides in unparsed and other databases, thus going deeper into the content of mobile devices, helping investigators uncover digital evidence that lives in hard-to-reach places, including brand-new applications, proprietary chat platforms and data sources that are not fully understood.

Deep Investigator automatically surfaces additional investigative leads with citations to the underlying evidence while applying Genesis’ built-in guardrails, ensuring responses remain grounded only in the provided evidence. Every query and action is logged with the user’s identity and timestamp, creating a complete audit trail. In the coming months Cellebrite expects to include new features and enhancements that add both expanded agentic capabilities and increased support for additional data sources. These innovations are designed to help investigators work smarter and faster, with an even better user experience.

About Cellebrite 

Cellebrite’s (Nasdaq: CLBT) mission is to protect communities, nations and businesses as a global leader in digital investigative and intelligence solutions. More than 7,000 global law enforcement agencies, defense and intelligence organizations and enterprises trust Cellebrite’s AI-powered software portfolio to make forensically sound digital data more accessible and actionable. Cellebrite technology allows customers to accelerate nearly 3 million legally sanctioned investigations annually, enhance sovereign security, elevate operational efficacy and efficiency, and enable advanced mobile research and application security. Available via cloud, on-premises and hybrid deployments, Cellebrite’s technology enables its customers around the globe to advance their missions, elevate public safety and safeguard data privacy. To learn more, visit www.cellebrite.com and https://investors.cellebrite.com, and find us on social media @Cellebrite.

Media

Jackie Labrecque

Director, PR and Executive Communications

jackie.labrecque@cellebrite.com  

+1 771.241.7010

Investor Relations

Andrew Kramer

Vice President, Investor Relations & Treasury

investors@cellebrite.com 

+1 973.206.7760

View original content to download multimedia:https://www.prnewswire.co.uk/news-releases/cellebrite-genesis-for-enterprise-now-generally-available-regional-availability-expands-to-more-global-markets-302854865.html

IBM Connects Its First Modular Cryogenic Systems in Milestone Toward Fault-Tolerant Quantum Computing

• New cryogenic quantum fridges designed to link hundreds of quantum chips.
• Cooled to below 15 millikelvin, more than 180 times colder than deep space, the build out marks a step forward in the engineering required for future quantum computers.
• Advances IBM’s quantum roadmap to deliver the world’s first fault-tolerant quantum computer in 2029.

YORKTOWN HEIGHTS, N.Y., Aug. 19, 2026 /PRNewswire/ — IBM (NYSE: IBM) today announced it has successfully joined and cooled down two cryogenic modules into a single environment. The new architecture is designed to scale into the modular, shared, and ultra-cold system required to link hundreds of quantum chips into a more powerful quantum computer capable of solving large problems. Its deployment is a milestone on IBM’s path to delivering IBM Quantum Starling in 2029, which is expected to be the world’s first fault-tolerant quantum computer and will integrate advances across error correction, processor design, decoding, and systems engineering.

Combined, the first two operational modules stand more than 8 feet tall and 8 feet wide, and initial tests demonstrated they can jointly cool down to 4 Kelvin (the temperature of liquid helium) in under 5 days, reaching a final temperature of below 15 millikelvin shortly after. Each module’s vacuum enclosure offers up to 12 times more wiring space than the most widely used IBM quantum systems, enabling more chip-to-chip connections both within and between modules.

IBM’s new box-shaped design allows modules to connect in a tight row and use this larger space to directly link quantum processors with IBM’s “L-coupler” technology. L-couplers connect separate quantum chips together to share information, communicate, and operate as part of a larger quantum computer.

By 2027, IBM’s quantum roadmap plans to use L-couplers to link multiple processors into a larger quantum computer with at least 1,000 programmable qubits, which are qubits that can be directly used to perform computations. Towards this goal, IBM will install IBM Quantum Nighthawk processors into the cryogenic modules later this year to expand operational performance testing. At the time Starling is delivered, IBM plans for each cryogenic module to house thousands of qubits.

IBM’s plans for Starling were introduced last year with a new error correction code that dramatically reduces the physical resources required for fault tolerance. Since then, the company’s progression has remained on course, including the demonstration of core hardware components and breakthroughs in efficient error-correction decoding.

“Bringing fault-tolerant quantum computers to industries depends on several fundamental advances,” said Jay Gambetta, Director of IBM Research and IBM Fellow. “The successful connection and operation of these cryogenic modules signals a leap forward in that direction and will accelerate our progress alongside continued innovation in quantum hardware, software, and algorithms.”

IBM expects its scalable cryogenic modules to help speed its pace of innovation. For example, three essential components of IBM Quantum System Two’s environment are built into the new architecture, but now in a way that allows each part to be independently tested, improved, and rapidly iterated.

The delivery of these new cryogenic quantum modules is further evidence that IBM is systematically delivering against its quantum roadmap, solving another one of the major hurdles required to accelerate its path to fault-tolerant quantum computing.

About IBM

IBM is a leading provider of global hybrid cloud and AI, and consulting expertise. We help clients in more than 175 countries capitalize on insights from their data, streamline business processes, reduce costs and gain the competitive edge in their industries. Thousands of governments and corporate entities in critical infrastructure areas such as financial services, telecommunications and healthcare rely on IBM’s hybrid cloud platform and Red Hat OpenShift to affect their digital transformations quickly, efficiently and securely. IBM’s breakthrough innovations in AI, quantum computing, industry-specific cloud solutions and consulting deliver open and flexible options to our clients. All of this is backed by IBM’s long-standing commitment to trust, transparency, responsibility, inclusivity and service. Visit www.ibm.com for more information.

Media contacts:

Dave Mosher

IBM

dave.mosher@ibm.com

Erin Angelini

IBM

edlehr@us.ibm.com 

View original content to download multimedia:https://www.prnewswire.co.uk/news-releases/ibm-connects-its-first-modular-cryogenic-systems-in-milestone-toward-fault-tolerant-quantum-computing-302854646.html

Laser-Guided Renal Artery Angioplasty Successfully Performed on a 60-Year Old Male Patient at Manipal Hospital Dhakuria

KOLKATA, India, Aug. 19, 2026 /PRNewswire/ — A 60-year-old male patient from Kolkata suffering from uncontrolled hypertension and hypertensive urgency, with blood pressure recorded at 220/120 mmHg despite multiple medications, underwent laser-guided renal artery angioplasty under the expertise of Dr Soumya Kanti Dutta, Interventional Cardiologist, Manipal Hospital Dhakuria.

The patient was admitted with severe headache, chest discomfort, vomiting, blurring of vision, vertigo, and semi-consciousness. A routine coronary angiography revealed coronary artery disease, and to investigate secondary causes of hypertension, renal angiography was conducted. This revealed a 100% thrombotic occlusion of the left renal artery. Conventional balloon angioplasty was not feasible due to the complete blockage. Therefore, the laser guided angioplasty was opted which would in the long run reduce the chances of repeated blockage and also would ensure faster recovery and less pain.

Dr Soumya Kanti Dutta revealed, “We decided to perform a laser-guided renal artery angioplasty. The laser technology successfully dissolved the clot, enabling placement of a stent at the renal artery ostium. This restored normal blood flow to the left kidney, resulting in improved kidney function, resumption of normal urination, and stabilization of blood pressure. “This innovative use of laser technology represents a major advancement in interventional cardiology and nephrology. Protecting kidney function is vital in managing complex cardiovascular cases, and this breakthrough offers new hope for patients with severe renal artery occlusion,” said Dr Dutta.

The patient is now stable and is doing well.

About the company

Manipal Hospitals is one of India’s leading integrated healthcare providers serving ~ 8 million patients annually, focussed on providing accessible, high-quality healthcare services. Manipal’s integrated network today has a pan-India footprint of 50 hospitals with over 13,400 licensed beds across 14 States & Union Territories. The network is India’s largest multispecialty hospital network by bed capacity, supported by a talented pool of 11,000+ doctors and an employee strength of over 25,000.

With a commitment to provide patient-centric care, Manipal Hospitals combines clinical expertise with advanced technology, research and innovation to serve a multitude of patients across the globe. Its continued focus on clinical quality and operational excellence is reflected in its NABH accreditation, with several of its hospitals also accredited by NABL and recognised for its excellence in nursing and emergency care.

Logo: https://mma.prnewswire.com/media/2987039/Manipal_Hospitals_Logo.jpg

View original content:https://www.prnewswire.com/in/news-releases/laser-guided-renal-artery-angioplasty-successfully-performed-on-a-60-year-old-male-patient-at-manipal-hospital-dhakuria-302855139.html